Literature DB >> 28721466

The MOGE(S) classification for cardiomyopathies: current status and future outlook.

Julian G Westphal1, Angelos G Rigopoulos2,3, Constantinos Bakogiannis4, Sarah E Ludwig1, Sophie Mavrogeni5, Boris Bigalke6, Torsten Doenst7, Matthias Pauschinger8, Carsten Tschöpe9,10,11, P Christian Schulze1, Michel Noutsias12,13.   

Abstract

Cardiomyopathies are complex diseases of multifactorial pathogenesis and have a high morbidity and mortality. Over the past decades, several revisions of classifications and definitions of cardiomyopathies have been proposed, primarily focusing on the phenotypic characterization of cardiomyopathies. The MOGE(S) classification system published in 2013 encompasses the classification of rapidly growing knowledge on genetic mutations, acquired causes (i.e., intramyocardial inflammation, viral infections), and further conditions involved in the induction of cardiomyopathies (e.g., storage diseases, toxicity). It is based on five attributes, including morphofunctional characteristics (M), organ involvement (O), genetic or familial inheritance pattern (G), etiological annotation (E), and optional information about the heart failure functional status (S). This review summarizes the development, the cornerstones of the MOGE(S) classification, and the published data on the clinical relevance of the MOGE(S) classification. We furthermore discuss new issues which might be considered for future updates of the MOGE(S) classification of cardiomyopathies.

Entities:  

Keywords:  Cardiomyopathies; Classification; Diagnosis; Genetic mutations; MOGE(S); Myocarditis

Mesh:

Substances:

Year:  2017        PMID: 28721466     DOI: 10.1007/s10741-017-9641-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  58 in total

1.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.

Authors:  R Wojnicz; E Nowalany-Kozielska; C Wojciechowska; G Glanowska; P Wilczewski; T Niklewski; M Zembala; L Polonski; M M Rozek; J Wodniecki
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Clinical application of WHF-MOGE(S) classification for hypertrophic cardiomyopathy.

Authors:  Anushree Agarwal; Rayan Yousefzai; M Fuad Jan; Chi Cho; Kambiz Shetabi; Michelle Bush; Bijoy K Khandheria; Timothy E Paterick; Shannon Treiber; Jasbir Sra; Paul Werner; Suhail Allaqaband; Tanvir Bajwa; A Jamil Tajik
Journal:  Glob Heart       Date:  2015-08-11

3.  The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers?

Authors:  Michele Pasotti
Journal:  J Am Coll Cardiol       Date:  2014-04-23       Impact factor: 24.094

Review 4.  Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.

Authors:  Job Verdonschot; Mark Hazebroek; Jort Merken; Yannick Debing; Robert Dennert; Hans-Peter Brunner-La Rocca; Stephane Heymans
Journal:  Eur J Heart Fail       Date:  2016-10-17       Impact factor: 15.534

5.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.

Authors:  L T Cooper; G J Berry; R Shabetai
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

6.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

Review 7.  Magnetic resonance imaging for characterizing myocardial diseases.

Authors:  Maythem Saeed; Hui Liu; Chang-Hong Liang; Mark W Wilson
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-31       Impact factor: 2.357

8.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

9.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

10.  LMNA-related dilated cardiomyopathy.

Authors:  Tatiyana Vaikhanskaya; Larysa Sivitskaya; Nina Danilenko; Oleg Davydenko; Tatsiyana Kurushka; Irina Sidorenko
Journal:  Oxf Med Case Reports       Date:  2014-09-03
View more
  13 in total

Review 1.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 2.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 3.  Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease.

Authors:  Amanda B Pullen; Jeevan Kumar Jadapalli; Boutayna Rhourri-Frih; Ganesh V Halade
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

4.  Diagnostic approaches for pericardial effusions : Beyond mere cytopathology.

Authors:  A G Rigopoulos; M Ali; S Sakellaropoulos; M Matiakis; M Teren; M Mammadov; B Ahmadzada; M Noutsias
Journal:  Herz       Date:  2017-12-15       Impact factor: 1.443

Review 5.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 6.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 7.  Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies.

Authors:  Julius L Katzmann; Peter Schlattmann; Angelos G Rigopoulos; Ewa Noutsias; Boris Bigalke; Matthias Pauschinger; Carsten Tschope; Daniel Sedding; P Christian Schulze; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 8.  Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Abdel-Rahman Torky; Marios Matiakis; Mammad Mammadov; Hannes Melnyk; Alexander Vogt; Renato de Vecchis; Boris Bigalke; Walter Wohlgemuth; Sophie Mavrogeni; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 9.  Advancements in the diagnostic workup, prognostic evaluation, and treatment of takotsubo syndrome.

Authors:  Muhammad Ali; Angelos G Rigopoulos; Khaldoun Ali; Ignatios Ikonomidis; George Makavos; Marios Matiakis; Hannes Melnyk; Elena Abate; Mammad Mammadov; Jan Lukas Prüser; Renato de Vecchis; Walter Wohlgemuth; Athanassios Manginas; Boris Bigalke; Sophie Mavrogeni; Daniel Sedding; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

Review 10.  Cardiac imaging in cardiotoxicity: a focus on clinical practice.

Authors:  George Makavos; Ignatios Ikonomidis; Ioannis Paraskevaidis; Michel Noutsias; John Palios; Angelos Rigopoulos; Konstantinos Katogiannis; John Parissis
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.